Peter Clausen

CIK: 0001605411

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)2 (66.7%)

Derivative conversions

Awards (A)1 (33.3%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

AURX

Nuo Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (3 total)

AURX
Nuo Therapeutics, Inc.
Jun 29, 2026
Award(A)
Option to purchase common stock
Direct
65K shares-
AURX
Nuo Therapeutics, Inc.
Jul 31, 2025
Exercise(M)
Direct
183.9K shares at avg. $0.40$74K
AURX
Nuo Therapeutics, Inc.
Aug 9, 2018
Exercise(M)
Option to purchase common stock
Direct
183.9K shares-

		Type	Shares	Price		Ownership
Jun 29, 2026	AURX Nuo Therapeutics, Inc.	Award(A) Option to purchase common stock	65,000	-	-	Direct
Jul 31, 2025	AURX Nuo Therapeutics, Inc.	Exercise(M)	183,853	$0.40	$73,541	Direct
Aug 9, 2018	AURX Nuo Therapeutics, Inc.	Exercise(M) Option to purchase common stock	183,853	-	-	Direct

1-3 of 3 transactions

About CLAUSEN PETER

CLAUSEN PETER (SEC CIK 0001605411) files insider reports with the SEC as CSO/COO of Nuo Therapeutics, Inc. (AURX).

Signal8 holds 2 ownership filings by CLAUSEN PETER, all Form 4s, filed between Aug 4, 2025 and Jul 2, 2026. Those filings report 3 transactions, from Aug 9, 2018 to Jun 29, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on CLAUSEN PETER's filings is in HOUSTON, TX.

Recent filings by CLAUSEN PETER

Jun 29, 2026: Grant or award of AURX derivative securities (Form 4, code A).
Jul 31, 2025: Option exercise of AURX shares (Form 4, code M).
Aug 9, 2018: Option exercise of AURX derivative securities (Form 4, code M).

Other insiders filing for Nuo Therapeutics, Inc. (AURX)

Pittman Scott M., Director
JORDEN DAVID EMERSON, CEO/CFO
WINZER C ERIC, Director
Mintz Paul, Director
SHEEDY CHARLES E, 10% Owner

How to read Form 4 transaction codes